Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") APRI (www.apricusbio.com) today
announced the sale of (1) Totect^® (dexrazoxane HCl), a marketed, injectable
treatment for anthracycline extravasation, and (2) NitroMist^® (nitroglycerin
sublingual aerosol), an FDA-approved nitrate vasodilator indicated for acute
relief of an attack or acute prophylaxis of angina pectoris due to coronary
artery disease. In line with its previously stated corporate strategy, the
Company is focusing its resources on commercializing its lead product
Vitaros^® (alprostadil 0.3% topical cream), for the treatment of erectile
dysfunction ("ED"), and on the development of Femprox^® (alprostadil 0.4%
topical cream), for the treatment of female sexual arousal disorder ("FSAD").
Totect^® was acquired by Biocodex USA ("Biocodex"), a subsidiary of a
privately-held, French pharmaceutical company, Biocodex Laboratories. Under
terms of the Biocodex agreement, Apricus Bio received an upfront payment at
closing and is eligible to receive royalties on net sales of Totect^® by
Biocodex through 2016, in exchange for Apricus Bio's sale of its
commercialization rights to Totect^® in North America and South America.
NitroMist^® was acquired by Mist Pharmaceuticals, LLC ("Mist"), a privately
held specialty pharmaceutical company. Mist will receive rights to
commercialize and market NitroMist^® in all countries outside the U.S., Canada
and Mexico.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsAsset Sales
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in